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Neuroysticercosis is the most common helminthic infection of the nervous system, and a leading cause of acquired epilepsy
worldwide. The disease occurs when humans become intermediate hosts of Taenia solium by ingesting its eggs from contaminated
food or, most often, directly from a taenia carrier by the fecal-to-oral route. Cysticerci may be located in brain parenchyma,
subarachnoid space, ventricular system, or spinal cord, causing pathological changes that are responsible for the pleomorphism of
neurocysticercosis. Seizures arethemost common clinical manifestation, but many patients present with focal deﬁcits, intracranial
hypertension, or cognitive decline. Accurate diagnosis of neurocysticercosis is possible after interpretation of clinical data together
with ﬁndings of neuroimaging studies and results of immunological tests. The introduction of cysticidal drugs have changed the
prognosis of most patients with neurocysticercosis. These drugs have shown to reduce the burden of infection in the brain and to
improve the clinical course of the disease in most patients. Further eﬀorts should be directed to eradicate the disease through the
implementation of control programs against all the interrelated steps in the life cycle of T. solium, including human carriers of the
adult tapeworm, infected pigs, and eggs in the environment.
1.Introduction
First recognized as a disease of pork in the ancient Greece,
neurocysticercosis is now considered the most common
helminthic disease of the central nervous system in humans
(Figure 1). The disease is endemic in most of the developing
world, where all the conditions favoring the transmission of
this parasitosis, including warm climate, severe poverty, and
illiteracy are combined. Indeed, population-based studies
carriedoutinruralvillagesofendemiccountrieshaveshown
that neurocysticercosis is the main reason for the excess
fraction of epilepsy seen in these areas, when compared
to the prevalence of epilepsy in developed countries [1–3].
The disease is also a health problem in urban centers of
developing countries, where neurocysticercosis is a major
cause of admissions to neurological hospitals [4]. Together
withthegrowingnumberofimmigrantsfromendemicareas,
there has been a recent increase in the number of patients
with neurocysticercosis in the developed world. Almost
90% of neurocysticercosis patients diagnosed in the US and
Europe are Latin American immigrants [5–7]. However,
neurocysticercosis has also been recognized in persons with
no history of travel to endemic areas, most of whom get
infected through a household contact harbouring the adult
Taenia solium in the intestine [8]. The unpredictable nature
of the immunological reaction of the host against cysticerci
aswellasthepleomorphiclesionsthatparasitesinduceinthe
centralnervoussystemmakeneurocysticercosisanintriguing
disease. During the past years, introduction of modern di-
agnostic techniques as well as development of cysticidal
drugs provoked a considerable interest in neurocysticercosis.
Here, we will review the most important aspects of this
parasitic disease, with emphasis on its pathogenesis, and on
recent advances of diagnosis and therapy.
2. Etiopathogenesis
The complex life cycle of Taenia solium involves two hosts.
Humans are the only deﬁnitive hosts for the adult tapeworm,
whereas both pigs and humans may act as intermediate hosts
for the larval form called cysticercus. In the normal cycle of
transmission, the adult T. solium inhabits the small intestine
of humans, where it is attached to the intestinal wall by its2 The Scientiﬁc World Journal
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Figure 1: World map showing countries where cysticercosis is
endemic.
potent suckers and hooks. Gravid proglottids are detached
fromthedistalendofthewormandarepassedwiththefeces,
liberating thousands of fertile eggs to the environment. In
placeswithdeﬁcientdisposalofhumanfeces,porkisfedwith
human feces containing T. solium eggs. Once in the intestinal
tract of the pork, the eggs lose their coats and liberate on-
cospheres which cross the intestinal wall and enter the
bloodstream, from where they are carried to the tissues and
evolve into cysticercus. Human consumption of improperly
cooked infected pork meat results in release of cysticerci in
thesmallintestine,where,bytheactionofdigestiveenzymes,
their scolices evaginate and attach to the intestinal wall.
After the scolex is attached, the proglottids begin to multiply
and will become mature approximately four months after
infection [9]. Humans can also be intermediate hosts of T.
solium after ingesting its eggs. Under these circumstances,
human cysticercosis develops. Humans acquire cysticercosis
from ingestion of food contaminated with T. solium eggs or
by the fecal-oral route in individuals harboring the adult
parasite in the intestine (Figure 2). Recent epidemiological
studies, showing clustering of patients with cysticercosis
around taeniasic individuals, have changed previous con-
ceptscreditingtheenvironmentasthemainsourceofhuman
contamination with T. solium eggs. Human cysticercosis
should be considered as a disease mostly transmitted from
person to person, and the role of infected pork is to per-
petuate the infection [10].
Cysticerci consist of two main parts, the vesicular wall
and the scolex [11]. After entering the central nervous sys-
tem, cysticerci are in a vesicular (viable) stage in which the
parasites have a transparent membrane, a clear vesicular
ﬂuid,andanormalinvaginatedscolex.Cysticercimayremain
viable for years or, as the result of the host’s immunological
attack, enter in a process of degeneration that ends with
their transformation into calciﬁcations. The ﬁrst stage of
involution of cysticerci is the colloidal stage, in which the
vesicular ﬂuid becomes turbid, and the scolex shows signs of
hyaline degeneration. Thereafter, the wall of the cyst thickens
and the scolex is transformed into mineralized granules; this
stage, in which the cysticercus is not longer viable, is called
the granular stage. Finally, the parasite remanents appear as
a mineralized nodule (calciﬁed stage) [12].
Vesicular cysticerci elicit little inﬂammatory reaction in
the surrounding tissue. In contrast, colloidal cysticerci are
often surrounded by a collagen capsule and by a mononu-
clear inﬂammatory reaction that includes the parasite itself.
The surrounding brain parenchyma shows astrocytic glio-
sis, microglial proliferation, edema, neuronal degenerative
changes, and perivascular cuﬃng of lymphocytes. When
parasites enter into the granular and calciﬁed stages, the
edema subsides but the astrocytic changes in the vicinity
of the lesions may become more intense, and epithelioid
cells appear and coalesce to form multinucleated giant cells
[13]. Meningeal cysticerci usually elicit a severe inﬂamma-
tory reaction in the subarachnoid space with formation
of an exudate composed of collagen ﬁbers, lymphocytes,
multinucleated giant cells, eosinophils, and hyalinized par-
asitic membranes leading to abnormal thickening of the
leptomeninges. This inﬂammation may be disseminated
inducing damage in the optic chiasm and cranial nerves
arising from the brainstem, as well as in small penetrating
arteries arising from the circle of Willis. The latter may cause
occlusion of the lumen of the vessel with the subsequent
development of a cerebral infarction [14]. The foramina
of Luschka and Magendie may also be occluded by the
thickened leptomeninges and parasitic membranes with the
subsequent development of obstructive hydrocephalus. Ven-
tricular cysticerci may also elicit an inﬂammatory reaction if
they are attached to the choroid plexus or to the ventricular
wall. The disrupted ependymal lining may protrude toward
the ventricular cavities blocking CSF transit, particularly
whenthesiteofprotrusionisatorneartheforaminaofMon-
ro or the cerebral aqueduct [13].
Some cysticercal antigens stimulate the production of
speciﬁc antibodies that form the basis for the immunological
diagnosis of cysticercosis, while others (particularly antigen
B) play a role in the evasion of the immune surveillance
against cysticerci [15]. In addition, it has been suggested the
occurrence of cellular immune dysfunction in patients with
neurocysticercosis, resulting from increased subpopulations
of CD8 T-lymphocytes, impaired proliferation of lympho-
cytes, and abnormal concentration of cytokines. It has been
hypothesized that this depressed cellular immunity may be
responsible for the reported association of neurocysticercosis
withconditionsresultingfromimmunodeﬁciencystates,and
with the development of gliomas [16]; in such cases, it has
been hypothesized that the intense glial proliferation around
the parasites, along with the suppression of the cellular im-
mune responses may cause inhibition of the immunological
surveillanceagainstcancer,leadingtomalignanttransforma-
tion of astrocytes [17].
3. ClinicalManifestations
The clinical pleomorphism of neurocysticercosis is mainly
related to individual diﬀerences in the number and location
ofthelesionswithintheCNSandtovariationsintheseverity
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Figure 2: Life cycle of Taenia solium showing the normal cycle of transmission, when humans act as deﬁnitive hosts and pigs as intermediate
hosts, and the aberrant cycle of transmission, when humans become intermediate hosts, developing cysticercosis.
manifestation of neurocysticercosis and may represent the
primary or sole manifestation of the disease in almost 70%
of patients [18]. Neurocysticercosis is a leading cause of
acquired epilepsy in the developing world and, as previously
noted, is partly responsible for the increased prevalence
of epilepsy seen in developing countries [1–3]. Seizures
are more frequently observed in patients with parenchymal
neurocysticercosis than in those with subarachnoid or
ventricular disease [19]. Epileptogenesis in patients with
calciﬁed neurocysticercosis has been a subject of debate
[20]. While calciﬁcations have been considered inert lesions,
recent data suggest that calciﬁed cysticerci are not clinically
inactive nor pathologically inert lesions, as they may cause
recurrent seizures when parasitic antigens trapped in the cal-
cium matrix are exposed to the host immune system due to
a process of calciﬁcation remodeling [21].
Focal neurological signs that vary according to the size,
number and location of the parasites have been described in
up to 20% patients with neurocysticercosis. Pyramidal tract
signs predominate, but sensory deﬁcits, language distur-
bances, involuntary movements, parkinsonian rigidity, and
signs of brainstem dysfunction, may occur in some patients.
These manifestations usually follow a subacute or chronic
course resembling that of a brain tumor and are most often
seen in patients with large subarachnoid cysts compressing
the brain parenchyma [22]. Stroke syndromes have also been
described in about 3% of patients with neurocysticercosis;
these are most often related to cerebral infarctions located in
the posterior limb of the internal capsule, the corona radiata,
or the brainstem [14]. Some patients with neurocysticercosis
develop intracranial hypertension associated or not with sei-
zures or focal neurological signs. The most common cause
of this syndrome is hydrocephalus, which may be either
related to cysticercotic arachnoiditis, granular ependymitis,
or ventricular cysts [22]. Intracranial hypertension also
occurs in patients with cysticercotic encephalitis, a severe
form of neurocysticercosis that occurs as the result of
a massive cysticerci infection of the brain parenchyma
inducing a severe immune response from the host. This
condition is more frequent among children and young wom-
en and is characterized by clouding of consciousness, sei-
zures, diminution of visual acuity, headache, vomiting, and
papilledema [23].
Some other patients with neurocysticercosis may present
psychiatric manifestations ranging from poor performance
on neuropsychological testing to a severe dementia [24].
BeforetheadventofCT,someofthesepatientswereadmitted
to psychiatric hospitals for several years until the correct
diagnosis was done at autopsy [25]. Patients with cysticerci
located in the sellar region present with ophthalmologic
and endocrinologic disturbances [26]. Spinal arachnoiditis
is characterized by root pain and weakness of subacuteonset,
and cysts in the spinal cord parenchyma usually present with
motor and sensory deﬁcits that vary according to the level
of the lesion [27]. Intraocular subretinal cysticerci produce
a progressive decrease of visual acuity or visual ﬁeld defects;
ocular cysts may induce vitritis, uveitis, and endophthalmitis
[28]. Massive cysticercal infection of striated muscles may4 The Scientiﬁc World Journal
produce generalized weakness associated with progressive
muscle enlargement [29].
4.Diagnosis
The advent of modern neuroimaging tests drastically
changed our diagnostic accuracy for neurocysticercosis (Fig-
ure 3). CT and MRI provide objective evidence on the
number and topography of lesions and their stage of
involution [30, 31]. Vesicular cysticerci appear on CT and
MRI as small and rounded cysts that are well demarcated
from the surrounding brain parenchyma. There is no edema
and no contrast enhancement. Many of these lesions have in
their interior an eccentric hyperdense nodule representing
the scolex, giving them a pathognomonic “hole-with-dot”
appearance. Colloidal and granular cysticerci appear as ill-
deﬁned lesions surrounded by edema; most of them show
a ring or a nodular pattern of enhancement after con-
trast medium administration. This pattern correspond is
commonly referred as to “cysticercus granuloma” [32]. A
particular neuroimaging pattern is that observed in patients
with cysticercotic encephalitis. CT and MRI show diﬀuse
brain edema, collapse of the ventricular system without
midline shift, and multiple small ring-like or nodular en-
hancing lesions disseminated within the brain parenchyma
[23]. Calciﬁed cysticerci normally appear on CT as small
hyperdense nodules without perilesional edema or abnormal
enhancement after contrast medium administration.
In patients with subarachnoid neurocysticercosis, the
most common neuroimaging ﬁnding is hydrocephalus re-
lated to inﬂammatory occlusion of Luschka and Magendie
foramina. The basal ﬁbrous arachnoiditis that is responsible
for the development of hydrocephalus is seen as focal or
diﬀuse areas of abnormal leptomeningeal enhancement.
CysticlesionslocatedwithinCSFcisternsusuallyhaveamul-
tilobulated appearance, displace neighboring structures, and
behave as mass occupying lesions [22]. MRA is a valuable
noninvasive imaging method to demonstrate segmental
narrowing or occlusion of intracranial arteries in patients
with subarachnoid neurocysticercosis [14]. Ventricular cys-
ticerci appear on CT as hypodense lesions that distort the
ventricular system causing asymmetric hydrocephalus. Since
many ventricular cysts are isodense with CSF, they only can
be inferred on the basis of distortion on the shape of the
ventricular cavities [33]. In contrast, most ventricular cysts
are readily visualized on MRI because the signal properties
of the cystic ﬂuid or the scolex diﬀer from those of the CSF
[34].Cystmobilitywithintheventricularcavitiesinresponse
to movements of the head, the “ventricular migration sign,”
facilitates the diagnosis of ventricular cysticercosis in some
cases. Intramedullary cysticerci appear on MRI as rounded
lesions that may have an eccentric hyperintense nodule
representing the scolex [30]. The periphery of the cyst
usually show abnormal enhancement after contrast medium
administration. The spinal cord is seen enlarged and, if the
scolex is not identiﬁed, it may be diﬃcult to diﬀerentiate
neurocysticercosis from spinal tumors. Leptomeningeal cysts
may be mobile within the spinal subarachnoid space and
may change their position during the exam according to
movements of the patient in the exploration table.
Demonstration that antibodies to species-speciﬁc anti-
gens of T. solium can be detected by enzyme-linked immu-
noelectrotransfer blot (EITB) assay stimulated investigators
to develop highly puriﬁed antigens of cysticercus to be used
in a reliable immune diagnostic test for cysticercosis [37].
The main weakness of this test is that it may be false-negative
in up to 50% of patients with a single cerebral cyst or in
those with calciﬁcations alone [32]. Another weakness is that
the test may be positive in patients who had been exposed
to the adult parasite without developing cysticercosis [31].
Detection of circulating parasitic antigens using monoclonal
antibodies has a poor sensitivity as a screening tool for the
diagnosis of neurocysticercosis; however, antigen detection
may be of value to monitor the response to cysticidal therapy
[38]. The frequency of positive stool exams for T. solium eggs
among patients with neurocysticercosis has varied from one
series to another and seems to be related to the severity of
infection [39, 40]. Speciﬁc coproantigen detection by ELISA
and PCR will improve the screening for T. solium carriers
among healthy individuals from endemic areas [38].
Despite the abovementioned advances in neuroimaging
and immune diagnostic tests, the diagnosis of neurocysticer-
cosis is a challenge in many patients. Clinical manifestations
are nonspeciﬁc, neuroimaging ﬁndings are most often not
pathognomonic, and serologic tests are faced with problems
related to relatively poor speciﬁcity and sensitivity. A set
of diagnostic criteria based on the objective evaluation of
clinical, radiological, immunological, and epidemiological
data has been proposed to provide the physicians with ele-
ments to diagnose patients with suspected neurocysticercosis
[35]. This set includes four categories of criteria—absolute,
major, minor, and epidemiologic—stratiﬁed according to
their individual diagnostic strengths. Absolute criteria allow
unequivocal diagnosis of neurocysticercosis, major criteria
strongly suggest the diagnosis but cannot be used alone to
conﬁrm the disease, minor criteria are frequent but nonspe-
ciﬁc manifestations of the disease, and epidemiologic criteria
refer to circumstantial evidence favoring the diagnosis of
cysticercosis. Interpretation of these criteria results in two
categoriesofdiagnosticcertainty—deﬁnitiveandprobable—
according to the likelihood that neurocysticercosis is present
in a given patient (Table 1).
5. Treatment
A single therapeutic approach is not expected to be useful
in every patient with neurocysticercosis. Characterization of
the disease in terms of viability of cysts, degree of the host’s
immune response to the parasite, and location and number
of lesions is important for rational therapy [41]. Therapy
usually include a combination of symptomatic and cysticidal
drugs. Surgery has also a role in the management of some
patients [42].
The introduction and subsequent widespread use of two
potent cysticidal drugs (praziquantel and albendazole) have






Figure 3: Imaging ﬁndings in patients with parenchymal brain cysticercosis, including: viable cysts showing the scolex (a), colloidal cyst
appearing as a ring-enhancing lesion (b), and calciﬁcations (c).
neurocysticercosis [43]. The initial regimen of praziquantel
at doses of 50mg/kg/day (given every 8 hours) for 15 days
was arbitrarily chosen [44]. It was then suggested that if
cysticerci are exposed to high concentrations of the drug
maintained for up to 6 hours by giving 3 individual doses of
25 to 30mg/kg at two-hour intervals, this might be suﬃcient
to destroy the parasites. While preliminary results with
this new regimen were encouraging [45], it seems that the
single-day course of praziquantel works better for patients
with a single parenchymal brain cyst, and that the 15-day
trial should be used for those with more than one cysts
[46]. Albendazole, the other cysticidal drug, was initially
administered at doses of 15mg/kg/day during one month
[47]. Further studies showed that the length of therapy could
be shortened to one week without lessening the eﬃcacy of
the drug [48], and even to three days if the patient has
a single brain cyst [49]. Albendazole has been superior to
praziquantel in trials comparing the eﬃcacy of these drugs
[50, 51]. Another advantage of albendazole is that it also
destroys subarachnoid and ventricular cysts [52]. In some of
these cases, particularly in patients with large subarachnoid
cysts, higher doses (up to 30mg/kg/day) or more prolonged,
or even repeated, courses of albendazole may be needed
[22, 53, 54].
Duetothebenignnatureofsomeformsofneur ocysticer -
cosis, the use of cysticidal drugs has been questioned, leading
to confusion and incorrect decisions in the management of
many patients. It has been claimed that cysticidal drugs only
destroy the cysts without modifying the clinical course of the
disease [55]. Nevertheless, more recent studies have shown
that cysticidal drugs also produce clinical improvement in
most patients. In a placebo-controlled trial, albendazole was
eﬀective for therapy of viable parenchymal brain cysticerci
[56]. Other controlled trials showed that the prognosis of
patients with colloidal parenchymal brain cysts is better after
therapy than when the disease is left untreated [36, 57, 58]. A
recentmeta-analysisofrandomizedtrialsevaluatedtheeﬀect
of cysticidal drugs on neuroimaging and clinical outcomes
of patients with neurocysticercosis [59]. According to that
meta-analysis, published evidence indicates that cysticidal
drug therapy results in better resolution of both colloidal
and vesicular cysticerci, in a lower risk of seizure recurrence
in patients with colloidal cysticerci, and in a reduction in
the rate of generalized seizures in patients with vesicular
cysticerci.
It must be remembered that some forms of neuro-
cysticercosis should not be treated with cysticidal drugs
[41]. These drugs may exacerbate the syndrome of intracra-
nial hypertension observed in patients with cysticercotic
encephalitis. In patients with both hydrocephalus and pa-
renchymalbraincysts,cysticidaldrugsmaybeusedonlyafter
a ventricular shunt has been placed to avoid further increases
of the intracranial pressure as a result of therapy. Cysticidal
drugs must be used with caution in patients with giant
subarachnoid cysticerci because the inﬂammatory reaction
developed by the host in response to the acute destruction of
theparasitemayoccludeleptomeningealvesselssurrounding
the cyst; concomitant steroid administration is mandatory
to avoid the hazard of a cerebral infarct. In patients with
ventricular cysts, the use of cysticidal drugs should be
individualized.Whilealbendazolesuccessfullydestroysmany
ventricular cysts, the inﬂammatory reaction may cause acute
hydrocephalus if the cysts are located within the fourth
ventricle or near the foraminae of Monro. Finally, pa-
tients with calciﬁcations alone should not receive cysticidal
drugs since these lesions represent already dead parasites
(Garcia et al., [41]).
The administration of a single ﬁrst-line antiepileptic
drug usually results in control of seizures in patients with
neurocysticercosis-related epilepsy. There is some evidence
that patients with viable intracranial cysts should ﬁrst
be treated with cysticidal drugs to achieve an adequate
control of seizures with antiepileptic drugs [18, 56]. The
optimal length of antiepileptic drug therapy in patients
with neurocysticercosis has not been settled. A prospective
study showed that up to 50% of patients with parenchymal
brain cysticerci successfully treated with cysticidal drugs
had relapses after withdrawal of antiepileptic drugs [60].6 The Scientiﬁc World Journal
Table 1: Diagnostic criteria and degrees of diagnostic certainty for
neurocysticercosis (Modiﬁed from: [35]).
Diagnostic criteria
Absolute
(i) Histologic demonstration of the parasite from biopsy of a brain
or spinal cord lesion.
(ii) Evidence of cystic lesions showing the scolex on neuroimaging
studies.
(iii) Direct visualization of subretinal parasites by fundoscopic
examination.
(iv) Spontaneous resolution of small single enhancing lesions.
Major
(i) Evidence of lesions highly suggestive of neurocysticercosis on
neuroimaging studies.
(ii) Positive serum immunoblot for the detection of anticysticercal
antibodies.
(iii) Resolution of intracranial cystic lesions after therapy with
albendazole or praziquantel.
Minor
(i) Evidence of lesions suggestive of neurocysticercosis on
neuroimaging studies.
(ii) Presence of clinical manifestations suggestive of
neurocysticercosis.
(iii) Positive CSF ELISA for detection of anticysticercal antibodies
or cysticercal antigens.
(iv) Evidence of cysticercosis outside the central nervous system.
Epidemiologic
(i) Individuals coming from or living in an area where
cysticercosis is endemic.
(ii) History of frequent travel to disease-endemic areas.
(iii) Evidence of household a contact with T. solium infection.
Degrees of diagnostic certainty
Deﬁnitive
(i) Presence of one absolute criterion.
(ii) Presence of two major plus one minor or one epidemiologic
criteria.
Probable
(i) Presence of one major plus two minor criteria.
(ii) Presence of one major plus one minor and one epidemiologic
criteria.
(iii) Presence of three minor plus one epidemiologic criteria.
Prognostic factors associated with seizure recurrence include
the development of parenchymal brain calciﬁcations and the
presence of both recurrent seizures and multiple brain cysts
before the institution of therapy. In patients with single-
enhancing lesions (colloidal cysts), the development of brain
calciﬁcation after therapy is also the main determinant for
seizure relapse after withdrawal of antiepileptic drugs; in
such cases, long-term antiepileptic treatment may be needed
[32].
6. Control Measures
Neurocysticercosis is common in areas where conditions
favoring the transmission of T. solium are found, including
deﬁcient disposal of human feces, low levels of education,
slaughtering of pigs without veterinary control, and presence
of free roaming pigs around households [19]. This parasitic
disease is potentially eradicable. To be eﬀective, however,
eradication programs must be directed to all the targets for
control, particularly human carriers of the adult tapeworm,
infected pigs, and eggs in the environment [61, 62]. Since
these targets represent interrelated steps in the life cycle of
T. solium, inadequate coverage of one of them may result in a
rebound in the prevalence of taeniosis/cysticercosis after the
program has been completed.
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